Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zipalertinib plus adjuvant chemotherapy versus placebo plus adjuvant chemotherapy after surgery for EGFR-mutant NSCLC
NL-OMON59120Phase 3Suspended
- Sponsor
- Taiho Oncology
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Zipalertinib plus adjuvant chemotherapy with Placebo plus adjuvant chemotherapy (2 arms). Primary endpoint: Disease-free survival. Started Apr 2026; status: suspended.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59120.